{"disease":{"id":"philadelphia-positive-chronic-myeloid-leukemia","name":"philadelphia positive chronic myeloid leukemia"},"drugs":{"marketed":[{"drug_id":"asciminib","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"asciminib-hydrochloride","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB HYDROCHLORIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ABL1 kinase of BCR::ABL1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05456191","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":568,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00171249","title":"An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":293,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03454503","title":"Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Hikma Pharmaceuticals LLC","has_results":false},{"nct_id":"NCT06427811","title":"Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01445080","title":"Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00588991","title":"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02115386","title":"Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03519984","title":"EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}